The company's lead programme is MTL-CEBPA, an saRNA designed to activate the CEBPA gene that is being tested in a phase 1b trial in hepatocellular carcinoma.
That project is focusing not on cancer but metabolic diseases, although MiNA's in-house efforts have already yielded one clinical candidate that activates the CEBPA gene, which codes for a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback